Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Desperate Measures: How To Soften The Impact Of No-Deal Brexit

Executive Summary

Building more cold chain warehouses, finding alternative sources of medicine supplies, and halting parallel exports to mitigate product shortages. Just some of the ideas for tackling the consequences of a no-deal Brexit scenario put forward by industry representatives at a recent parliamentary committee hearing.

You may also be interested in...



No-Deal Brexit: UK Can Wave Goodbye To Savings From Parallel Imports

It is being suggested that a no-deal Brexit would put an end to parallel imports to the UK, thereby reducing price competition and pushing up costs of medicines prescribed on the NHS.

Make Them In Europe: The French Solution To Drug Shortages

The French Senate has produced a set of recommendations for tackling the growing problem of medicine shortages in France and the rest of Europe. The industry body Leem says shortages have many causes and that it will work with other stakeholders to find long-term solutions.

No-Deal Brexit Means ‘Re-Planning A Whole Industry,’ Says ABPI Chief

Mike Thompson, head of the Association of the British Pharmaceutical Industry, outlined his industry’s concerns over medicines stockpiling, batch testing, tariffs, regulatory collaboration and other issues at a parliamentary committee hearing on the implications of a no-deal Brexit.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS124146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel